C3L-00368
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67.44969199
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.340
- MYOGENESIS+0.230
- COAGULATION+0.220
- PANCREAS_BETA_CELLS+0.200
- KRAS_SIGNALING_DN+0.180
- APOPTOSIS+0.150
- P53_PATHWAY+0.150
- TNFA_SIGNALING_VIA_NFKB+0.140
- CHOLESTEROL_HOMEOSTASIS+0.130
- NOTCH_SIGNALING+0.120
Top 10 suppressed
- MYC_TARGETS_V2-0.640
- G2M_CHECKPOINT-0.560
- E2F_TARGETS-0.550
- MYC_TARGETS_V1-0.550
- MTORC1_SIGNALING-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.470
- MITOTIC_SPINDLE-0.410
- ANGIOGENESIS-0.390
- PI3K_AKT_MTOR_SIGNALING-0.290
- GLYCOLYSIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.862 |
| 2 | TCGA-CF-A47S-01A-11R-A23W-07 | — | — | 0.858 |
| 3 | TCGA-97-7941-01A-11R-2187-07 | — | cohortA1 | 0.851 |
| 4 | C3N-03038 | — | cohortA1 | 0.850 |
| 5 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.845 |
| 6 | TCGA-L9-A50W-01A-12R-A39D-07 | — | cohortA1 | 0.841 |
| 7 | TCGA-55-8512-01A-11R-2403-07 | — | cohortA1 | 0.841 |
| 8 | TCGA-97-A4M1-01A-11R-A24X-07 | — | cohortA1 | 0.838 |
| 9 | TCGA-67-4679-01B-01R-1755-07 | — | cohortA1 | 0.836 |
| 10 | TCGA-91-8497-01A-11R-2403-07 | — | cohortA1 | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |